Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

International Validation of Two Non-motor Scales in PD (NFS and SPARK)

Sponsor: Insel Gruppe AG, University Hospital Bern

NCT ID: NCT04366804

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 60 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor

In plain English

This study is checking whether two questionnaires — the Non-motor Fluctuations Scale (NFS) and SPARK — work well for measuring non-movement symptoms in people with Parkinson's disease. Non-movement symptoms are things like sleep, mood or memory problems. The study is being run internationally by Insel Gruppe AG, University Hospital Bern, in Switzerland.

Who can take part

  • You give written informed consent to take part
  • You have Parkinson's disease, diagnosed using the MDS (Movement Disorder Society) criteria
  • You are aged between 30 and 75 years
  • You speak the language the questionnaires are given in fluently

Who may not be able to

  • You have Parkinson's disease dementia (shown by a MoCA — Montreal Cognitive Assessment — score below 24)

What taking part involves

  • • Not stated — ask the trial team

Time commitment: Not stated — ask the trial team

Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.

Type of study
Observing health over time
Ages
30 Years to 75 Years
Who
All
Number of participants
300
Started
2020-12-03
Last checked
2025-04

Plain English Summary

What is this study?

  • • Testing a new treatment for parkinson's disease
  • • Clinical study - 300 participants
  • • The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD)

Who can take part?

  • • Ages 30 Years to 75 Years
  • • Diagnosed with parkinson's disease

Where?

  • • London - King's College London

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD).

More detail

This project is a prospective international multicentre study to validate two new rating scales in different languages: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale. The project population consists a minimum of 300 PD patients with and without fluctuations in the participant countries: Spain, Germany, France, Switzerland, Romania and Greece. The NFS is specifically designed to detect neuropsychiatric fluctuations between off- and on-medication condition in PD. It is composed of 20 items, 10 items measuring the on-neuropsychological symptoms and 10 items for the off-neuropsychological manifestations. The validation of this scale, based on the most frequently experienced symptoms by the patients, would allow a crucial breakthrough in the improvement of management of PD patients. Shame and embarrassment are poorly recognized by physicians in PD. PD-related shame and embarrassment may emerge from motor and non-motor symptoms, from self-perception of inadequacy due to loss of autonomy and need for help, or from perceived deterioration of body image. The current available scales are not specific for PD. Based on reports of persons affected with PD and a literature review about shame and stigmatization in PD a 25-items self-questionnaire for shame and embarrassment in PD was created. The scale includes 6 different subscales (1. Shame arising from PD symptoms; 2. Shame arising from the increasing physical dependence and need for help induced by PD; 3. Shame arising from the patient's assumption of breaking certain social rules; 4. Shame arising from the deteriorated body image; 5. Consequence of related shame and embarrassment on patients' health-related quality of life; 6. Stigmatization). The validation of this scale will give a tool for physicians and researchers to better understand the impact of PD on patient's quality of life.

Parkinson's DiseaseNon-motor Symptoms

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 30 Years - 75 Years
  • Who can join: All genders

What the study is looking for

  • ✓Written agreement to take part;
  • ✓PD, according to the MDS criteria;
  • ✓Age of participants \> 30 and \< 75 years;
  • ✓Being fluent in the language in which the scales are applied.

Who cannot take part

  • ✗1\. Presence of PD dementia (defined as MoCA score \< 24).
See the full criteria
Inclusion Criteria: 1. Written informed consent; 2. PD, according to the MDS criteria; 3. Age of participants \> 30 and \< 75 years; 4. Being fluent in the language in which the scales are applied. Exclusion Criteria: 1\. Presence of PD dementia (defined as MoCA score \< 24).

Where Is This Study? (1 UK site)

King's College London

London WC2R 2LS, United Kingdom

Recruiting
Hospital R&D contact (matched)

Jasmine Palmer

kch-tr.research@nhs.net0203 299 1980

How to Get in Touch

Ines Debove, MD

Sponsor contact

CONTACT

+41 31 63 2 79 24 ines.debove@insel.ch
Data sourced from ClinicalTrials.gov · Last verified: 2025-04